Notable Health vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Mateo healthcare AI platform automating patient intake, insurance verification, care gap identification, and post-visit follow-up for health systems via EHR-connected AI agents.
About
Notable Health is a San Mateo-based healthcare AI company that provides health systems with an automation platform that handles repetitive clinical and administrative tasks — patient intake, pre-visit questionnaires, insurance verification, care gap identification, and post-visit follow-up — using AI agents deployed on health system infrastructure. Notable's platform connects to EHR systems to understand each patient's care context and proactively sends personalized communications and automated workflows at the right moments in the patient journey. By automating tasks that currently consume significant time from nurses, medical assistants, and front desk staff, Notable enables health systems to manage the same patient volume with fewer administrative staff or improve throughput without hiring. The company has documented millions of automated care actions with customers including Intermountain Health and Stanford Medicine. Founded in 2017, Notable raised over $100M from investors including F-Prime Capital, BOND, and Oak HC/FT, and competes with Olive AI (now closed) and Regard in the healthcare automation market.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.